Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
BACKGROUND: LMTM is being developed as a treatment for AD based on inhibition of tau aggregation. OBJECTIVES: To examine the efficacy of LMTM as monotherapy in non-randomized cohort analyses as modified primary outcomes in an 18-month Phase III trial in mild AD. METHODS: Mild AD patients (n = 800) were randomly assigned to 100 mg twice a day or 4 mg twice a day. Prior to unblinding, the Statistical Analysis Plan was revised to compare the 100 mg twice a day as monotherapy subgroup (n = 79) versus 4 mg twice a day as randomized (n = 396), and 4 mg twice a day as monotherapy (n = 76) versus 4 mg twice a day as add-on therapy (n = 297), with strong control of family-wise type I error. RESULTS: The revised analyses were statistically significant at the required threshold of p < 0.025 in both comparisons for change in ADAS-cog, ADCS-ADL, MRI atrophy, and glucose uptake. The brain atrophy rate was initially typical of mild AD in both add-on and monotherapy groups, but after 9 months of treatment, the rate in monotherapy patients declined significantly to that reported for normal elderly controls. Differences in severity or diagnosis at baseline between monotherapy and add-on patients did not account for significant differences in favor of monotherapy. CONCLUSIONS: The results are consistent with earlier studies in supporting the hypothesis that LMTM might be effective as monotherapy and that 4 mg twice a day may serve as well as higher doses. A further suitably randomized trial is required to test this hypothesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig.4 Annualized rate of whole brain atrophy (expressed as %) over months 0–6 and months 12–18 in monotherapy patients. The rates are compared with those reported by Leung et al. for mild AD and normal elderly controls [20].](https://figures.cochat.ai/paper-figures/aeac5f76d82b4c29866d5b5dc4b39bb2/potential-of-low-dose-leuco-methylthioninium-bis-hydromethanesulphonate-lmtm-figure-4.jpg)
![Fig.5 Voxel-based morphometric comparison showing regions of greater atrophy in patients receiving LMTM as monotherapy [N = 157] (A) or as add-on to approved treatments for AD [N = 610], (B) in TRx-237-005 compared with elderly controls [N = 244] from the ongoing Aberdeen birth cohort studies [23, 26], controlled for age, sex and total intracranial volume of each individual. (C) Voxel-based morphometric comparison of monotherapy and add-on patients in TRx-237-005. Data are displayed at a significance threshold corrected for family-wise error at the whole brain level at p < 0.05.](https://figures.cochat.ai/paper-figures/6e1dee94609a44d685c3236eb32611c9/potential-of-low-dose-leuco-methylthioninium-bis-hydromethanesulphonate-lmtm-figure-5.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Two earlier studies (NCT01689233 and NCT01689246) conducted on participants with mild AD and mild to moderate AD, respectively, indicated that the drug demonstrated good safety and potential benefits as a monotherapy.466,467”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [466]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Tau protein has the capacity to form toxic proteolytically resistant oligomers which seed further tau aggregation in an autocatalytic manner [10] and propagate the pathology into previously healthy brain regions [11], most likely accounting for the stereotyped pattern of spread of pathology [6, 7, 12].”
BackgroundPosner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“Patients were also assessed at all visits for suicidal ideation and intent using the Columbia-Suicide Severity Rating Scale [17], and were systematically monitored for potential serotonin syndrome using a rating scale derived from four published diagnostic criteria [18], because of a theoretical potential for serotoni…”
MethodA comparison of observational studies and randomized, controlled trials.
Benson, K., & Hartz, A. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422506 · Cited by 2,347
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113 · cited 1×
“In Alzheimer’s disease (AD), clinical deterioration [1], imaging markers of loss of neuronal function [2–4], and progression of brain atrophy as measured by MRI volumetry [5] progress in parallel with the accumulation of aggregated tau.”
BackgroundSelf-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 3×
“as monotherapy or as add-on therapy was also compared with that reported for mild AD in the placebo arms of recent Phase III studies [21, 22] and currently available ADNI data (https://ida.”
ResultDefeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676 · cited 1×
“Since measurable cohort differences in diagnosis or severity do not appear to explain the treatment differences we report, we believe that the within- and between-study consistency of the results cannot be dismissed lightly, particularly given the urgent need for new treatments in AD [56].”
Self-citationPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 3×
“as monotherapy or as add-on therapy was also compared with that reported for mild AD in the placebo arms of recent Phase III studies [21, 22] and currently available ADNI data (https://ida.”
ResultAcetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.036 · Cited by 1,404 · cited 1×
“Ascending cholinergic projections originating predominantly from nucleus basalis provide both direct activation [33] and indirect inhibitory modulation of cortical pyramidal cells [34].”
BackgroundAssociations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
Landau, S. M., Harvey, D., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., Weiner, M. W., & Jagust, W. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.002 · Cited by 750 · cited 5×
“Using the same methodology as in the ADNI program [24], baseline 18F-FDG-PET SUVR in inferior temporal gyrus normalized with respect to pons was less than that reported for mild AD [24] in both monotherapy (p = 0.”
BackgroundMethodResultInfluentialProteopathic tau seeding predicts tauopathy in vivo
Holmes, B. B., Furman, J. L., Mahan, T. E., Yamasaki, T. R., Mirbaha, H., Eades, W. C., Belaygorod, L., Cairns, N. J., Holtzman, D. M., & Diamond, M. I. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411649111 · Cited by 696
Research works printed but not linked: 1
- Gharid A, Atamna H (2011) Methylene blue induces mitochondrial complex IV and improves cognitive function and grip strength in old mice. In Neurodegeneration: Theory, Disorders and Treatments, McNeill AS, ed. AS Nova Science Publishers, Hauppauge, NY, pp. 63– 85.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
“The results of TRx 237–005 phase III clinical trials showed that the agent may be effective as a monotherapy since the brain atrophy rate of AD patients declined after 9 months of treatment.(137) ACI-35 (AC Immune/Janssen) and AADvac1 (Axon Neuroscience SE) are vaccines that target the hyperphosphorylated tau protein,…”
BackgroundSavelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer’s disease
Kaur, D., Sharma, V., & Deshmukh, R. (2019) · Inflammopharmacology · doi:10.1007/s10787-019-00580-x · Cited by 484
Economic burden of Alzheimer disease and managed care considerations
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88482 · Cited by 398
Tau-targeting therapies for Alzheimer disease: Current status and future directions
Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371
“Although none of the trials produced positive results, a revised report was released that purported to show efficacy 153,155,156 .”
BackgroundYiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., & Pelidou, S.-H. (2019) · Biomedicines · doi:10.3390/biomedicines7040097 · Cited by 330
“One outstanding exception in this trend is the low dose leuco-methylthioninium bis (hydromethanesulphonate) (LMTM) monotherapy for treatment of mild AD, which is currently assessed in a phase 3 clinical trial [23].”
BackgroundInfluentialChallenges and hopes for Alzheimer’s disease
Tatulian, S. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.016 · Cited by 291
Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
Athar, T., Al Balushi, K., & Khan, S. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06512-9 · Cited by 247
Tapia-Rojas, C., Cabezas-Opazo, F., Deaton, C. A., Vergara, E. H., Johnson, G. V. W., & Quintanilla, R. A. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.005 · Cited by 191
“the usefulness of methylene blue derivatives in treating AD and other tauopathies are needed (Wilcock et al., 2018).”
Peng, Y., Jin, H., Xue, Y.-H., Chen, Q., Yao, S.-Y., Du, M.-Q., & Liu, S. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1206572 · Cited by 165
“Moreover, two Phase III studies [(NCT01689246)/the European Union Clinical Trials Registry (2012-002866-11), (NCT01689233) and the European Union Clinical Trials Registry (21012-002847- 28)] confirmed that TRx0237 improved the cognition in patients with mild to moderate AD, such as changes in ADAS-Cog and Alzheimer’s…”
BackgroundInfluentialClinical Research on Alzheimer’s Disease: Progress and Perspectives
Sun, B.-L., Li, W.-W., Zhu, C., Jin, W.-S., Zeng, F., Liu, Y.-H., Bu, X.-L., Zhu, J., Yao, X.-Q., & Wang, Y.-J. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0249-z · Cited by 161
An Overview on the Clinical Development of Tau-Based Therapeutics
Medina, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041160 · Cited by 156
Buchholz, S., & Zempel, H. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13784 · Cited by 137
Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
“Meanwhile, another phase III clinical trial (NCT01689233) for LMTM as a monotherapy for mild to moderate AD demonstrated promising results, indicating that LMTM might be effective in future studies [192].”
BackgroundTau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues
Samudra, N., Lane-Donovan, C., VandeVrede, L., & Boxer, A. L. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168553 · Cited by 131
“Tau aggregation disruption aims to prevent the paired helical filament conformation observed in NFTs, and a derivative of methylene blue (LMTM), which prevents this in mouse models, was evaluated in a phase III trial of behavioral variant FTD without evidence of efficacy (110).”
MethodNew Insights Into Drug Discovery Targeting Tau Protein
Soeda, Y., & Takashima, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.590896 · Cited by 134
Niewiadomska, G., Niewiadomski, W., Steczkowska, M., & Gasiorowska, A. (2021) · Life · doi:10.3390/life11010028 · Cited by 131
Kulkarni, A. S., Aleksić, S., Berger, D. M., Sierra, F., Kuchel, G. A., & Barzilai, N. (2022) · Aging Cell · doi:10.1111/acel.13596 · Cited by 137
“…show promise in reducing cognitive decline in mild and moderate Alzheimer's disease, while D+Q have shown beneficial effects in small open- label pilot clinical trials in idiopathic pulmonary fibrosis and CKD (Hickson et al., 2019; Justice et al., 2019; Wilcock et al., 2018; Wischik et al., 2015).”
BackgroundInfluentialDisease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
“Two of these trials are assessing methylene blue in different formulations and though methylene blue is touted as an aggregation inhibitor, it may have more complex effects on chaperone systems [166, 167].”
BackgroundJiang, S., & Bhaskar, K. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.586731 · Cited by 114
Gandini, A., Bartolini, M., Tedesco, D., Martinez-Gonzalez, L., Roca, C., Campillo, N. E., Zaldivar-Diez, J., Perez, C., Zuccheri, G., Miti, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00610 · Cited by 107
Ivashko-Pachima, Y., Hadar, A., Grigg, I., Korenková, V., Kapitansky, O., Karmon, G., Gershovits, M., Sayas, C. L., Kooy, R. F., Attems, J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0563-5 · Cited by 107
“clearance therapies [15] are also being developed, however, Tau monotherapy may not suffice [44, 45].”
Toader, C., Tătaru, C. P., Munteanu, O., Șerban, M., Covache-Busuioc, R.-A., Ciurea, A. V., & Enyedi, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312613 · Cited by 122
Advances in Alzheimer’s disease’s pharmacological treatment
Filho, C. E. C., Loss, L. B., Pereira, C. M., Rossoni, J. V., Barcelos, R. M., Chiarelli-Neto, O., da Silva, B. S., Ambrósio, R. P., Castro, F. C. D. A. Q., Teixeira, S. F., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1101452 · Cited by 123
“Although LMTM combines superior pharmacological properties with TAI activity than MTC, phase 3 trial showed no benefit to AD patients and led to treatment discontinuation (Gauthier et al., 2016; Wilcock et al., 2018).”
BackgroundGonzález, J. F., Alcántara, A. R., Doadrio, A. L., & Sánchez-Montero, J. M. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1623201 · Cited by 98
“analog of the reduced form of MB (leuco-methylene blue, LMT), which is actually in Phase 3 [71,72].”
BackgroundMullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer’s Disease
Toniolo, S., Sen, A., & Husain, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239318 · Cited by 94
“LMTM (or Methylene Blue or TRx0237), an aggregator inhibitor, did not prove beneficial in large human trials in AD [102], even if subsequent analyses suggested a possible positive effect on rates of brain atrophy [103], and currently a phase 1b/2a is ongoing in mild cognitive impairment (MCI) and mild AD (Table 1).”
BackgroundWang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92
Targeting tau: clinical trials and novel therapeutic approaches
VandeVrede, L., Boxer, A. L., & Polydoro, M. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134919 · Cited by 90
Multipronged diagnostic and therapeutic strategies for Alzheimer's disease
Ramesh, M., & Govindaraju, T. (2022) · Chemical Science · doi:10.1039/d2sc03932j · Cited by 94
Oxygen metabolism abnormality and Alzheimer's disease: An update
Liu, G., Yang, C., Wang, X., Chen, X., Wang, Y., & Le, W. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102955 · Cited by 93
“Leuco-methylthionium and methylthioninium are tau inhibitors with potential therapeutic value for AD [210,211].”
BackgroundComplement System in Alzheimer’s Disease
Shah, A., Kishore, U., & Shastri, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413647 · Cited by 73
A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies
Imbimbo, B. P., Ippati, S., Watling, M., & Balducci, C. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12453 · Cited by 75
Alzheimer’s disease clinical trial update 2019–2021
Pleen, J., & Townley, R. A. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10790-5 · Cited by 74
Current and evolving treatment strategies for the Alzheimer disease continuum
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88481 · Cited by 66
The genetic architecture of multimodal human brain age
Wen, J., Zhao, B., Yang, Z., Erus, G., Skampardoni, I., Mamourian, E., Cui, Y., Hwang, G., Bao, J., Boquet-Pujadas, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46796-6 · Cited by 74
“Another drug is the LMTM (TRx0237) — a second-generation tau protein aggregation inhibitor currently being tested in a phase-3 clinical trial (trial number: NCT03446001) for treating AD and frontotemporal dementia 44 .”
BackgroundAlzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics
Manap, A. S. A., Almadodi, R., Sultana, S., Sebastian, M. G., Kavani, K. S., Lyenouq, V. E., & Shankar, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1429211 · Cited by 84
FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau filaments
Kaniyappan, S., Tepper, K., Biernat, J., Chandupatla, R. R., Hübschmann, S., Irsen, S., Bicher, S., Klatt, C., Mandelkow, E.-M., & Mandelkow, E. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00389-1 · Cited by 58
Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities
Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61
Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target
Oakley, S. S., Maina, M. B., Marshall, K. E., Al-Hilaly, Y. K., Harrington, C. R., Wischik, C. M., & Serpell, L. C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.590754 · Cited by 61
“LMTM was found to produce better outcomes when given as a monotherapy than as an add-on to symptomatic AD treatments (269, 270).”
BackgroundSelf-citationXiao, S., Lu, Y.-F., Wu, Q., Yang, J., Chen, J., Zhong, S., Eliezer, D., Tan, Q., & Wu, C. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.02.210 · Cited by 58
Wischik, C. M., Bentham, P., Gauthier, S., Miller, S., Kook, K., & Schelter, B. O. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.63 · Cited by 55
“Phase 2 and 3 trials demonstrated a benign safety profile (19, 20).”
BackgroundResultSelf-citationThe Potentials of Methylene Blue as an Anti-Aging Drug
Xue, H., Thaivalappil, A., & Cao, K. (2021) · Cells · doi:10.3390/cells10123379 · Cited by 68
“Another non-randomized cohort analysis has been performed more recently, which showed that the brain atrophy rate in patients with mild AD declined after a 9-month treatment [63].”
BackgroundScarpa, M., Hesse, S., & Bradley, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2019.12.003 · Cited by 62
Peña‐Díaz, S., García‐Pardo, J., & Ventura, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030839 · Cited by 60
Chen, Y., Jin, H., Chen, J., Li, J., Găman, M., & Zou, Z. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02600-y · Cited by 64
Huang, Y., Wen, J., Ramirez, L.-M., Gümüşdil, E., Pokhrel, P., Man, V. H., Ye, H., Han, Y., Liu, Y., Li, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41241-6 · Cited by 57
Status and future directions of clinical trials in Alzheimer's disease
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.03.022 · Cited by 47
Modeling Prion-Like Processing of Tau Protein in Alzheimer’s Disease for Pharmaceutical Development
Wischik, C. M., Schelter, B. O., Wischik, D., Storey, J. M. D., & Harrington, C. R. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170727 · Cited by 54
“The results of Study 005 have been reported recently [56].”
ResultSelf-citationSchelter, B. O., Shiells, H., Baddeley, T. C., Rubino, C. M., Ganesan, H., Hammel, J., Vuksanović, V., Staff, R. T., Murray, A. D., Bracoud, L., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190772 · Cited by 47
Self-citationPHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer’s Disease
Luna‐Viramontes, N. I., Campa-Córdoba, B. B., Ontiveros‐Torres, M. Á., Harrington, C. R., Villanueva‐Fierro, I., Guadarrama-Ortíz, P., Garcés‐Ramírez, L., de la Cruz, F., Hernándes‐Alejandro, M., Martínez-Robles, S., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00247 · Cited by 50
“Whereas the development of drugs directed against the phosphorylation of the tau protein may involve certain risks, targeting the aggregation of tau proteins with compounds that fail to affect the normal association of tau with microtubules offers another therapeutic target (Wischik et al., 2014; Wilcock et al., 2018).”
BackgroundSelf-citationProtein clearance strategies for disease intervention
Hommen, F., Bilican, S., & Vílchez, D. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02431-y · Cited by 51
Disentangling tau: One protein, many therapeutic approaches
Lane‐Donovan, C., & Boxer, A. L. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00321 · Cited by 50
Tondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 46
“Also, molecules that inhibit tau-fibrillation failed to induce clinical improvement [89].”
BackgroundThe structure and phase of tau: from monomer to amyloid filament
Zeng, Y., Yang, J., Zhang, B., Gao, M., Su, Z., & Huang, Y. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03681-x · Cited by 46
Al‐Hilaly, Y. K., Pollack, S. J., Rickard, J. E., Simpson, M. C., Raulin, A., Baddeley, T. C., Schellenberger, P., Storey, J. M. D., Harrington, C. R., Wischik, C. M., et al. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.08.010 · Cited by 46
Self-citationLiu, N., Liang, X., Chen, Y., & Xie, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102199 · Cited by 52
Mitochondria as a promising target for developing novel agents for treating Alzheimer's disease
Shevtsova, E. F., Maltsev, A. V., Vinogradova, D. V., Shevtsov, P. N., & Бачурин, С. О. (2020) · Medicinal Research Reviews · doi:10.1002/med.21715 · Cited by 42
“to believe that MB and it bioisosteric analogs may have a high potential for the treatment of ischemic and hypoxic disorders, AD, and some other neurodegenerative diseases.(30,31,41,42) It is noteworthy that MB significantly reduces the level of abnormal aggregates of proteins such as huntingtin, α‐synuclein, tau, and…”
BackgroundNew Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer’s Disease
Penke, B., Szűcs, M., & Bogár, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065383 · Cited by 43
“The treatment was unsuccessful in a group of 800 patients with mild AD in phase 3 clinical trials [135].”
BackgroundCurrent druggable targets for therapeutic control of Alzheimer's disease
Gupta, G. L., & Samant, N. P. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106549 · Cited by 41
Xu, Y., Zhao, M.-N., Zhou, D., Zheng, T., & Zhang, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111360 · Cited by 38
Zhou, L., Flores, J., Noël, A., Beauchet, O., Sjöström, P. J., & LeBlanc, A. C. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0856-6 · Cited by 37
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 40
A Review of Recent Advances in the Management of Alzheimer’s Disease
Skylynn, T., Lee, C. S., Metchikoff, E., Razdan, V., Suliman, G., Rivera, D., Pinto, A., & Pemminati, S. (2024) · Cureus · doi:10.7759/cureus.58416 · Cited by 64
“LMTM was studied as a monotherapy in an 18-month Phase III clinical trial in a non-randomized cohort of patients with AD [27].”
MethodGenetic Variants and Oxidative Stress in Alzheimer’s Disease
Kowalska, M., Wize, K., Prendecki, M., Lianeri, M., Kozubski, W. P., & Dorszewska, J. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200224121447 · Cited by 36
Shiells, H., Schelter, B. O., Bentham, P., Baddeley, T. C., Rubino, C. M., Ganesan, H., Hammel, J., Vuksanović, V., Staff, R. T., Murray, A. D., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191173 · Cited by 35
Self-citationPharmacological Modulators of Tau Aggregation and Spreading
Dominguez‐Meijide, A., Vasili, E., & Outeiro, T. F. (2020) · Brain Sciences · doi:10.3390/brainsci10110858 · Cited by 41
“Among these modulators, leuco-methylthioninium bis(hydromethanesulfonate) (LMTM) [187] reached phase III clinical trials for FTD [188,189].”
BackgroundAlzheimer’s Disease: From Molecular Mechanisms to Promising Therapeutic Strategies
Ivanova, A. V., Kutuzova, A. D., Kuzmichev, I. A., & Abakumov, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199444 · Cited by 35
Stem cell therapies for Alzheimer's disease: is it time?
Wang, S., Lee, C., & Lim, H. K. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000478 · Cited by 37
“Results from antitau therapy (hydromethanesulfonate: LMTM) were equivocal; initial phase III trials showed negative results, but modified primary outcomes in an 18-month phase III trial suggested that LMTM might improve cognitive function in patients with Alzheimer’s disease [10,11].”
Therapeutics of Alzheimer’s Disease: Recent Developments
Burns, S., Selman, A., Sehar, U., Rawat, P., Reddy, A. P., & Reddy, P. H. (2022) · Antioxidants · doi:10.3390/antiox11122402 · Cited by 40
“Wilcock GK and colleague’s study on examining the efficacy of LMTM as monotherapy in non-randomized cohort analyses as modified primary outcomes in an 18-month Phase III trial in mild AD support the hypothesis that LMTM could be effective as monotherapy and that the administration of a 4 mg dose twice a day may serve…”
MethodPhenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimer’s Disease
Górecki, L., Uliassi, E., Bartolini, M., Janočková, J., Hrabinová, M., Hepnarová, V., Prchal, L., Múčková, Ľ., Pejchal, J., Karasová, J. Ž., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00184 · Cited by 31
Three‐repeat and four‐repeat tau isoforms form different oligomers
Shahpasand‐Kroner, H., Portillo, J., Lantz, C., Seidler, P. M., Sarafian, N., Loo, J. A., & Bitan, G. (2022) · Protein Science · doi:10.1002/pro.4257 · Cited by 35
Schwab, K., Frahm, S., Horsley, D., Rickard, J. E., Melis, V., Goatman, E. A., Magbagbeolu, M., Douglas, M., Leith, M., Baddeley, T. C., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00447 · Cited by 33
“Both forms of the methylthioninium (MT) moiety have been tested clinically in Alzheimer’s disease in Phase 2 and 3 clinical trials (Wischik et al., 2015; Gauthier et al., 2016; Wilcock et al., 2018) and have been found to have potential efficacy as monotherapy.”
BackgroundSelf-citationRiedel, G., Klein, J., Niewiadomska, G., Kondak, C., Schwab, K., Lauer, D., Magbagbeolu, M., Steczkowska, M., Zadrożny, M., Wydrych, M., et al. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200224120926 · Cited by 31
Self-citationAlzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 37
“Small molecules such as methylene blue ( Figure 7) [224] and related analogs [225,226] proved to inhibit tau aggregation in vitro.”
Kennedy, R., Cutter, G., Fowler, M. E., & Schneider, L. S. S. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.4080 · Cited by 31
Cai, N., Chen, J., Bi, D., Gu, L., Yao, L., Li, X., Li, H., Xu, H. Y., Hu, Z., Liu, Q., et al. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b07022 · Cited by 29
Бачурин, С. О., Aksinenko, A. Y., Махаева, Г. Ф., & Shevtsova, E. F. (2023) · Russian Chemical Bulletin · doi:10.1007/s11172-023-3718-0 · Cited by 34
Vuksanović, V., Staff, R. T., Ahearn, T. S., Murray, A. D., & Wischik, C. M. (2019) · International Journal of Neural Systems · doi:10.1142/s0129065718500557 · Cited by 34
Self-citationInvasive and non-invasive therapies for Alzheimer’s disease and other amyloidosis
Pandey, G., & Ramakrishnan, V. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00752-y · Cited by 31
The Structure Biology of Tau and Clue for Aggregation Inhibitor Design
Wang, D., Huang, X., Yan, L., Zhou, L., Chang, Y., Wu, J., Su, Z., & Huang, Y. (2021) · The Protein Journal · doi:10.1007/s10930-021-10017-6 · Cited by 30
Thioxanthenone-based derivatives as multitarget therapeutic leads for Alzheimer's disease
Tonelli, M., Catto, M., Sabaté, R., Francesconi, V., Laurini, E., Pricl, S., Pisani, L., Miniero, D. V., Liuzzi, G. M., Gatta, E., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115169 · Cited by 26
Mackey-Alfonso, S. E., Butler, M. J., Taylor, A., Williams-Medina, A. R., Muscat, S. M., Fu, H., & Barrientos, R. M. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.07.021 · Cited by 26
“…modifying treatments, both of which are controversial and have had varying degrees of success (Wilcock, 2003; Hansen, 2008; Aisen, 2011; Rafii, 2011; Birks and Harvey, 2006; Novak, 2021; van Dyck, 2023; Budd Haeberlein, 2022; Ltd et al., 2014; Wilcock, 2018; Doody, 2013; Herrmann et al., 2011).”
BackgroundTau Protein-Targeted Therapies in Alzheimer’s Disease: Current State and Future Perspectives
Pluta, R. M., & Ułamek-Kozioł, M. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch4 · Cited by 40
“Recently, a second phase-III study in patients with Alzheimer’s disease treated orally, twice daily, (NCT01689233) showed no effect on primary endpoints (40).”
BackgroundRecognizing and treating atypical Parkinson disorders
Armstrong, M. J., & McFarland, N. R. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00016-9 · Cited by 26
Venkatramani, A., Mukherjee, S., Kumari, A., & Panda, D. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.01.172 · Cited by 21
Yeboah, F., Kim, T., Bill, A., & Dettmer, U. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104543 · Cited by 22
An evaluation of hydromethylthionine as a treatment option for Alzheimer’s disease
Hashweh, N., Bartochowski, Z., Khoury, R., & Grossberg, G. T. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1719066 · Cited by 23
Impact of New Drugs for Therapeutic Intervention in Alzheimer’s Disease
Olloquequi, J., Ettcheto, M., Cano, A. C., Sánchez‐López, E., Carrasco, M., Espinosa-Jiménez, T., Beas‐Zárate, C., Gudiño‐Cabrera, G., Ureña‐Guerrero, M. E., Verdaguer, E., et al. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2705146 · Cited by 27
“NCT01055392 [26] TRx0237 (Phase 3) TauRx Therapeutics Ltd Prevents tau aggregation and attenuates downstream pathological consequences of aberrant tau.”
BackgroundThe next step of neurogenesis in the context of Alzheimer’s disease
Moradi, H. R., Hajali, V., Khaksar, Z., Vafaee, F., Forouzanfar, F., & Negah, S. S. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06520-9 · Cited by 20
Penny, L. K., Lofthouse, R. A., Arastoo, M., Porter, A., Palliyil, S., Harrington, C. R., & Wischik, C. M. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00417-w · Cited by 21
“The inhibitors (e.g., hydromethylthionine mesylate) prevent the self-aggregation cascade of tau from the physiologic monomeric form to the pathologic oligomers and neurofibrillary tangles [27, 28].”
BackgroundSelf-citationBerrocal, M., Corbacho‐Cuello, I., Gutiérrez‐Merino, C., & Mata, A. M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.07.012 · Cited by 22
Imbimbo, B. P., Ippati, S., & Watling, M. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1793755 · Cited by 21
Pathogenesis, Animal Models, and Drug Discovery of Alzheimer’s Disease
Xia, Z.-D., Ma, R.-X., Wen, J.-F., Zhai, Y.-F., Wang, Y.-Q., Wang, F.-Y., Liu, D., Zhao, X.-L., Sun, B., Jia, P., et al. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-230326 · Cited by 19
“TRx0237 is a drug approved by the FDA for the treatment of malaria, which has potential in the treatment of AD [186].”
Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics
Arar, S. H., Haque, M. A., & Kayed, R. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26561 · Cited by 23
“…is an ongoing promising therapeutic is being investigated more often as an inhibitor for tau causing disease aggregation with failing attempts in phase 2/3 clinical trials due to low efficicy, 4,8,260 and slow cognitive or functional decline in subjects with mild to moderate AD (reported 2022).”
Hashmi, M. U., Ahmed, R., Mahmoud, S., Ahmed, K., Bushra, N. M., Ahmed, A., Elwadie, B., Madni, A., Saad, A. B., & Abdelrahman, N. G. (2023) · Cureus · doi:10.7759/cureus.46732 · Cited by 24
“According to a recent study, a subset of patients who were administered leuco-methylthioninium bis-hydromethanesulfonate (LMTM), a modified version of MB, as the sole treatment, exhibited a significant reduction in the extent of illness advancement compared to the control group [23].”
BackgroundInfluential
Metadata
- Authors
- Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., Storey, J. M. D., Harrington, C. R., & Wischik, C. M.
- Affiliations
- University of Oxford (GB)
- Douglas Mental Health University Institute (CA)
- University of Geneva (CH)
- Beijing Institute for Brain Disorders (CN)
- TauRx (United Kingdom) (GB)
- Moebius-Consult, Baar, Switzerland
- Birmingham and Solihull Mental Health NHS Foundation Trust (GB)
- Salamandra LLC, Bethesda, MD, USA
- University of Aberdeen (GB)
- University of Cambridge (GB)
- CSD Biostatistics, Tucson, AZ, USA
- Aberdeen Biomedical Imaging Centre, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK
- BioClinica, Lyon, France
- RadMD, New York, NY, USA
- MNI Imaging, New Haven, CT, USA
- Corresponding author
- Wischik, Claude M.
- ORCID
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2017-11-28
- Volume
- 61
- Issue
- 1
- Pages
- 435-457
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5734125
- OpenAlex
- W2768871557
- Cited by
- 219
- References
- 57
- Citations by year
- 2026: 16 · 2025: 26 · 2024: 30 · 2023: 31 · 2022: 28 · 2021: 27 · 2020: 27 · 2019: 17 · 2018: 16 · 2017: 1
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- TauRx Pharmaceuticals
- European Commission
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- MeSH terms
- Mental Status and Dementia Tests, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Humans, International Cooperation, Male, Methylene Blue, Middle Aged, Antipsychotic Agents, Cohort Studies, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.